Amber Salter1, Robert J Fox2, Scott D Newsome3, June Halper4, David K B Li5, Pamela Kanellis6, Kathleen Costello7, Bruce Bebo7, Kottil Rammohan8, Gary R Cutter9, Anne H Cross1. 1. Washington University School of Medicine in St Louis, St Louis, Missouri. 2. Cleveland Clinic, Cleveland, Ohio. 3. Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Consortium of MS Centers, Hackensack, New Jersey. 5. The University of British Columbia, Vancouver, British Columbia, Canada. 6. MS Society of Canada, Toronto, Ontario, Canada. 7. National Multiple Sclerosis Society, Chicago, Illinois. 8. University of Miami School of Medicine, Miami, Florida. 9. The University of Alabama at Birmingham, Birmingham.
Abstract
Importance: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections. Objective: To examine outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with MS. Design, Setting, and Participants: This analysis used deidentified, cross-sectional data on patients with MS and SARS-CoV-2 infection reported by health care professionals in North American academic and community practices between April 1, 2020, and December 12, 2020, in the COVID-19 Infections in MS Registry. Health care professionals were asked to report patients after a minimum of 7 days from initial symptom onset and after sufficient time had passed to observe the COVID-19 disease course through resolution of acute illness or death. Data collection began April 1, 2020, and is ongoing. Exposures: Laboratory-positive SARS-CoV-2 infection or highly suspected COVID-19. Main Outcomes and Measures: Clinical outcome with 4 levels of increasing severity: not hospitalized, hospitalization only, admission to the intensive care unit and/or required ventilator support, and death. Results: Of 1626 patients, most had laboratory-positive SARS-CoV-2 infection (1345 [82.7%]), were female (1202 [74.0%]), and had relapsing-remitting MS (1255 [80.4%]). A total of 996 patients (61.5%) were non-Hispanic White, 337 (20.8%) were Black, and 190 (11.7%) were Hispanic/Latinx. The mean (SD) age was 47.7 (13.2) years, and 797 (49.5%) had 1 or more comorbidity. The overall mortality rate was 3.3% (95% CI, 2.5%-4.3%). Ambulatory disability and older age were each independently associated with increased odds of all clinical severity levels compared with those not hospitalized after adjusting for other risk factors (nonambulatory: hospitalization only, odds ratio [OR], 2.8 [95% CI, 1.6-4.8]; intensive care unit/required ventilator support, OR, 3.5 [95% CI, 1.6-7.8]; death, OR, 25.4 [95% CI, 9.3-69.1]; age [every 10 years]: hospitalization only, OR, 1.3 [95% CI, 1.1-1.6]; intensive care unit/required ventilator support, OR, 1.3 [95% CI, 0.99-1.7]; death, OR, 1.8 [95% CI, 1.2-2.6]). Conclusions and Relevance: In this registry-based cross-sectional study, increased disability was independently associated with worse clinical severity including death from COVID-19. Other risk factors for worse outcomes included older age, Black race, cardiovascular comorbidities, and recent treatment with corticosteroids. Knowledge of these risk factors may improve the treatment of patients with MS and COVID-19 by helping clinicians identify patients requiring more intense monitoring or COVID-19 treatment.
Importance: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections. Objective: To examine outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with MS. Design, Setting, and Participants: This analysis used deidentified, cross-sectional data on patients with MS and SARS-CoV-2 infection reported by health care professionals in North American academic and community practices between April 1, 2020, and December 12, 2020, in the COVID-19Infections in MS Registry. Health care professionals were asked to report patients after a minimum of 7 days from initial symptom onset and after sufficient time had passed to observe the COVID-19 disease course through resolution of acute illness or death. Data collection began April 1, 2020, and is ongoing. Exposures: Laboratory-positive SARS-CoV-2 infection or highly suspected COVID-19. Main Outcomes and Measures: Clinical outcome with 4 levels of increasing severity: not hospitalized, hospitalization only, admission to the intensive care unit and/or required ventilator support, and death. Results: Of 1626 patients, most had laboratory-positive SARS-CoV-2 infection (1345 [82.7%]), were female (1202 [74.0%]), and had relapsing-remitting MS (1255 [80.4%]). A total of 996 patients (61.5%) were non-Hispanic White, 337 (20.8%) were Black, and 190 (11.7%) were Hispanic/Latinx. The mean (SD) age was 47.7 (13.2) years, and 797 (49.5%) had 1 or more comorbidity. The overall mortality rate was 3.3% (95% CI, 2.5%-4.3%). Ambulatory disability and older age were each independently associated with increased odds of all clinical severity levels compared with those not hospitalized after adjusting for other risk factors (nonambulatory: hospitalization only, odds ratio [OR], 2.8 [95% CI, 1.6-4.8]; intensive care unit/required ventilator support, OR, 3.5 [95% CI, 1.6-7.8]; death, OR, 25.4 [95% CI, 9.3-69.1]; age [every 10 years]: hospitalization only, OR, 1.3 [95% CI, 1.1-1.6]; intensive care unit/required ventilator support, OR, 1.3 [95% CI, 0.99-1.7]; death, OR, 1.8 [95% CI, 1.2-2.6]). Conclusions and Relevance: In this registry-based cross-sectional study, increased disability was independently associated with worse clinical severity including death from COVID-19. Other risk factors for worse outcomes included older age, Black race, cardiovascular comorbidities, and recent treatment with corticosteroids. Knowledge of these risk factors may improve the treatment of patients with MS and COVID-19 by helping clinicians identify patients requiring more intense monitoring or COVID-19 treatment.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-29 Impact factor: 19.103
Authors: Anja Strangfeld; Martin Schäfer; Philip C Robinson; Jinoos Yazdany; Pedro M Machado; Milena A Gianfrancesco; Saskia Lawson-Tovey; Jean W Liew; Lotta Ljung; Elsa F Mateus; Christophe Richez; Maria J Santos; Gabriela Schmajuk; Carlo A Scirè; Emily Sirotich; Jeffrey A Sparks; Paul Sufka; Thierry Thomas; Laura Trupin; Zachary S Wallace; Sarah Al-Adely; Javier Bachiller-Corral; Suleman Bhana; Patrice Cacoub; Loreto Carmona; Ruth Costello; Wendy Costello; Laure Gossec; Rebecca Grainger; Eric Hachulla; Rebecca Hasseli; Jonathan S Hausmann; Kimme L Hyrich; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Lianne Kearsley-Fleet Journal: Ann Rheum Dis Date: 2021-01-27 Impact factor: 19.103
Authors: L Silvia Muñoz-Price; Ann B Nattinger; Frida Rivera; Ryan Hanson; Cameron G Gmehlin; Adriana Perez; Siddhartha Singh; Blake W Buchan; Nathan A Ledeboer; Liliana E Pezzin Journal: JAMA Netw Open Date: 2020-09-01
Authors: Farhan Chaudhry; Helena Bulka; Anirudha S Rathnam; Omar M Said; Jia Lin; Holly Lorigan; Eva Bernitsas; Jacob Rube; Steven J Korzeniewski; Anza B Memon; Phillip D Levy; Lonni Schultz; Adil Javed; Robert Lisak; Mirela Cerghet Journal: J Neurol Sci Date: 2020-09-19 Impact factor: 3.181
Authors: Meryl Waldman; Maria Jose Soler; Clara García-Carro; Liz Lightstone; Tabitha Turner-Stokes; Megan Griffith; Joan Torras; Laura Martinez Valenzuela; Oriol Bestard; Colin Geddes; Oliver Flossmann; Kelly L Budge; Chiara Cantarelli; Enrico Fiaccadori; Marco Delsante; Enrique Morales; Eduardo Gutierrez; Jose A Niño-Cruz; Armando J Martinez-Rueda; Giorgia Comai; Claudia Bini; Gaetano La Manna; Maria F Slon; Joaquin Manrique; Alejandro Avello; Raul Fernandez-Prado; Alberto Ortiz; Smaragdi Marinaki; Carmen Rita Martin Varas; Cristina Rabasco Ruiz; Milagros Sierra-Carpio; Rebeca García-Agudo; Gema Fernández Juárez; Alexander J Hamilton; Annette Bruchfeld; Constantina Chrysochou; Lilian Howard; Smeeta Sinha; Tim Leach; Irene Agraz Pamplona; Umberto Maggiore; Paolo Cravedi Journal: Kidney360 Date: 2021-12-03
Authors: Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp Journal: Nervenarzt Date: 2021-07-23 Impact factor: 1.214
Authors: K Allen-Philbey; A Stennett; T Begum; A C Johnson; R Dobson; G Giovannoni; S Gnanapavan; M Marta; I Smets; B P Turner; D Baker; J Mathews; K Schmierer Journal: Mult Scler Relat Disord Date: 2021-05-18 Impact factor: 4.808